[go: up one dir, main page]

EP0038192A1 - 5-Alkylsalicylanilides derivatives and method for inhibiting the growth of microorganisms - Google Patents

5-Alkylsalicylanilides derivatives and method for inhibiting the growth of microorganisms Download PDF

Info

Publication number
EP0038192A1
EP0038192A1 EP81301586A EP81301586A EP0038192A1 EP 0038192 A1 EP0038192 A1 EP 0038192A1 EP 81301586 A EP81301586 A EP 81301586A EP 81301586 A EP81301586 A EP 81301586A EP 0038192 A1 EP0038192 A1 EP 0038192A1
Authority
EP
European Patent Office
Prior art keywords
composition
organism
formula
mel
microorganism
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP81301586A
Other languages
German (de)
French (fr)
Other versions
EP0038192B2 (en
EP0038192B1 (en
Inventor
Robert A. Coburn
Richard T. Evans
Robert J. Genco
Armando Batista
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Research Foundation of the State University of New York
Original Assignee
Research Foundation of the State University of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26837870&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP0038192(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/140,098 external-priority patent/US4287191A/en
Application filed by Research Foundation of the State University of New York filed Critical Research Foundation of the State University of New York
Priority to AT81301586T priority Critical patent/ATE8989T1/en
Publication of EP0038192A1 publication Critical patent/EP0038192A1/en
Application granted granted Critical
Publication of EP0038192B1 publication Critical patent/EP0038192B1/en
Publication of EP0038192B2 publication Critical patent/EP0038192B2/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/42—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/69—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C65/32—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups
    • C07C65/40—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing keto groups containing singly bound oxygen-containing groups

Definitions

  • This invention relates to compositions and methods for killing or controlling the growth of microorganisms and more particularly relates to certain substituted salicylamide compositions having anti-bacterial activity which are particularly useful in controlling the growth of microorganisms related to dental plaques and associated diseases.
  • compositions and methods have been sought for killing and controlling the growth of microorganisms, particularly those related to disease.
  • the compositions which have been discovered for this purpose all have had one or more disadvantages.
  • the compositions have not been effective against all undesirable microorganisms such as disease causing bacteria, have permitted certain microorganisms to develop an immunity or tolerance for the composition, have been more toxic than desirable, have caused allergic reactions in the host, or have been expensive and difficult to manufacture or purify.
  • compositions used to control the growth of bacteria related to dental plaques and associated diseases are either insufficiently effective, are too toxic or both.
  • Toxic as used here in means that the composition causes damage to an organism, especially a human, which uses the composition to control the growth of an undesired microorganism whether the composition is applied topically or otherwise.
  • aromatic amine chlorinated and brominated compounds are to be avoided due to toxicity and sometimes carcinogenicity often associated with this type of compound.
  • compounds which have low enough toxicity to be used as oral antiseptics are usually not sufficiently effective at low concentrations to treat dental plaques and associated diseases.
  • chlorhexidine An example of a compound which contains chlorine attached to a phenyl amine ring which is or has been used as an oral antiseptic is chlorhexidine. Another compound which has been used is tribromsalan a brominated salicylanilide. This compound is effective but still is not as effective as desirable in killing or sufficiently inhibiting the growth of plaque causing organisms at concentrations as low as desired.
  • Compounds which are used as oral antiseptics which contain chlorine or bromine but not in a phenyl ring are cetylpyridinium chloride and domiphen bromide. These compounds are also insufficiently effective in controlling microorganisms associated with dental plaque, especially in dentifrice compositions in which these compounds often become deactivated.
  • Other antiseptics which contain chlorine attached to a phenyl ring but are not generally used in oral antiseptics are hexachlorophene and trichlocarban.
  • a non-halogenated oral antiseptic is hexylresorcinal. Hexylresorcinal is insufficiently effective against plaque forming organisms and in addition has a toxicity which is higher than desired. There are many other antiseptics but most have toxicities which are too high, especially for oral use.
  • Halogenated salicylanilides have been studied as possible antiseptic compounds; however most halogenated salicylanilides have now been banned by the United States Food and Drug Administration from certain over-the counter-products. This ban is due to adverse effects resulting from the use of such products. For example tetrachlorosalicylanilide has been shown to produce allergic reactions in man and certain other hologenated salicylanilides have been reported to produce photo-allergic reactions.
  • a novel composition which may be but is not necessarily halogenated with fluorine, chlorine or bromine and which is an effective antiseptic with low toxicity in its preferred forms and which very surprisingly in its preferred forms is very effective against organisms associated with dental plaques, with forms of caries, with periodontal diseases such as gingivitis and with other oral infections.
  • the compositions are believed to be especially effective against gram-positive bacteria.
  • compositions comprise certain 5-Alkylsalicylanilides and more particularly comprise the compounds encompassed by the following generic formula:
  • Z is a substituted phenyl ring of from 6 to 30 carbon atoms including substituents
  • R is a substituted or unsubstituted n-alkyl or phenyl group of from 4 to 30 carbon atoms including substitutents.
  • compositions of the invention have a partition coefficient greater than 4 and the substituted moieties in the phenyl ring of the Z group have a combined overall electron withdrawing effect on the phenyl ring of the Z group.
  • compositions are effective antiseptics against a wide range of bacteria and the preferred compositions surprisingly are especially effective against a prevalent microorganism in dental plaque, Actinomyces viscosus(A.vis.), and in addition are effective against some (but not necessarily all) other organisms associated with periodontal diseases often including Actinomyces naeslundii (A.naes.), Streptococcus mutans (S.mut.), Actinomyces israelii (A.isra.), Bacteroides melan- ino R enicus intermedius (B.mel.int.), and Streptoccus sanguis (S.sang).
  • the invention further comprises a method for inhibiting the growth of microorganisms by exposing a microorganisms whose growth is affected by the composition of the invention to a sufficient concentration of the composition to inhibit growth.
  • the present invention is concerned with certain antiseptic compositions and particularly certain 5 alkyl derivatives of salicylanilides. These compositions all have at least some antiseptic properties and the preferred compositions have excellent antiseptic properties especially against certain microorganisms associated with dental plaques and associated oral diseases. Furthermore many of these compositions are characterised by having low toxicity to mammals. Additionally the invention includes the method for controlling the growth of microorganisms by contacting sensitive microorganisms with a composition of the invention for a sufficient time to kill or inhibit the growth or reproduction of the organisms. The contact of the microorganism with the composition may be accomplished in either in vivo or in vitro environments.
  • compositions comprise certain 5-Alkylsalicylanilides and more particularly comprise the compounds encompassed by the following generic formula:
  • Z is a substituted phenyl ring of from 6 to 30 carbon atoms including substituents
  • R is a substituted or unsubstituted n-alkyl or phenyl group of from 4 to 30 carbon atoms including substituents.
  • compositions of the invention have a partition coefficient greater than 4 and the substituted moieties in the phenyl ring of the Z group have a combined overall electron withdrawing effect on the phenyl ring of the Z group.
  • Partition coefficient of a composition as used herein is the log 10 P where P is the ratio of the concentration of the composition in octanol to the concentration of the composition in water in a two phase octanol-water system.
  • a partition coefficient of 4 therefore means that the ratio of the concentration of the composition in octanol to the concentration of the composition in water is 10 4 or 10,000 to 1.
  • the partition coefficient is a measure of the Iipophylic character of the compound.
  • the preferred compositions of the invention are lipophylic as indicated by a partition coefficient of greater than 4. The partition coefficient is however usually less than 10.
  • Moieties which may replace hydrogen, as previously described, which contain only carbon and hydrogen are all hydrocarbon moieties including alkyl, alkenyl, alkynyl, alkyldienyl, cycloalkyl, phenyl, alkylphenyl, naphthyl, anthryl, phenanthryl, fluoryl, steroid groups, and combinations of these groups with each other and with polyvalent hydrocarbon groups such as alkylene, alkylidene and alkylidyne groups. Specific examples of such groups are:
  • Moieties containing oxygen which may replace hydrogen as previously described include hydroxy, acyl or keto, ether, epoxy, carboxy, and ester containing groups.
  • moieties containing sulfur are the sulfur containing acids and acid ester groups, thioether groups, mercapto groups and thioketo groups. Specific examples of such groups are: -SCH 2 CH 3 , -CH 2 S(CH 2 ) 4 CH 3 , -SO 3 CH 2 CH 3 , -SO 2 CH 2 CH 3 , -CH 2 COSH, -SH,
  • moieties containing nitrogen are amino groups, the nitro group, azo groups, ammonium groups, amide groups, azido groups, isocyanate groups, cyano groups and nitrile groups. Specific examples of such groups are:
  • moieties containing halogen are chloro, bromc ; fluoro, iodo groups and any of the moieties previously described where a hydrogen or a pendant alkyl group is substituted by a halo group to form a stable substituted moiety.
  • halogen containing moieties are:
  • any of the above moieties can be substituted into each other in either a monovalent substitution or by loss of hydrogen in a polyvalent substitution to form another monovalent moiety which can replace hydrogen in the organic compound or radical.
  • “Lower alkyl” as used herein means an alkyl group of from 1 through 5 carbon atoms.
  • "- ⁇ " as used herein represents a phenyl ring.
  • R- is a saturated or unsaturated, halogenated or unhalogenated n-alkylene or phenylene group containing 4 through 20 carbon atoms.
  • -R- may be cycloalkylene, e.g.cyclohexylene.
  • Examples of preferred -R- groups are: -0-, -(CII 2 ) 4 -, -(CH 2 ) 6 - ' and -(CH 2 ) 8 -.
  • Other -R- groups are -(CH 2 ) 6 (CCl 2 )-,-(CF 2 ) 6 -,and -(CCl 2 ) 8 -. It is apparent that the foregoing are only examples of possible -R- groups.
  • A is independently at each occurrence -H, -OH, -halogen, lower alkoxy, lower alkyl, -SH, thioalkyl, phenyl,phenoxy, -NH 2 , lower amino or lower acyl group.
  • A is most preferably methyl (-CH 3 ) or -H.
  • additional lipophylic groups or elements must be present so that the overall hydrophylic-lipophylic balance of the R group decidely favors solubility in fats or oils.
  • lipophylic means the tendency to be attracted to fats or oils and as is well known hydrophylic means to be attracted to water.
  • the R group should in fact be sufficiently lipophylic to give an overall lipophylic character to the composition, i.e. a partition coefficient greater than 4.
  • m is an integer of from 1 through 3 and in the preferred embodiments of the invention is usually 1 since pendant groups from the -R - moiety usually do not add greatly to the antimicrobial character of the compounds and even if they do the same pendant groups often can increase toxicity to mammals.
  • Pendant groups which are hydrophylic in particular have been found to reduce anti-microbial activity unless more lipophylic groups are added to the R moiety to offset them.
  • Y is independently at each occurrence -H, lower alkyl, halogenated lower alkyl, -N0 2 , -CN, -halogen, lower acyl, -S0 2 R", or -S0 3 R" where R" is lower alkyl or halogenated lower alkyl, provided that at least one of Y is not H or lower alkyl.
  • Y is not chlorine or bromine when applied to humans due to the increased toxicity or carcinogenicity often associated with halogenated phenyl rings. Halogen has however been found to sometimes even further increase antimicrobial activity and thus is nevertheless sometimes used especially when the compound is used only in in-vitro environments.
  • Halogen especially fluorine
  • An example of a very good Y group is -CF 3 .
  • all good Y groups are electron withdrawing groups and desirably are not strongly hydrophylic or water solubilizing groups.
  • a particularly good Y group is -N0 2 especially when it is in the 4' position on the phenyl ring.
  • Another very good Y group is -1' especially when located in all of the Y positions on the phenyl ring.
  • Examples of other compounds highly suitable for use in accordance with the invention are those compounds wherein m is 1 or 2, at least one A is not -H and Y is independently at each occurrence -H, -halogen, -N0 2 , -CN, halogenated lower alkyl, -CHO, or lower acyl.
  • -R- may be cycloalkylene as previously discussed.
  • the method in accordance with the present invention for inhibiting the growth of microorganisms and especially bacterial organisms comprises contacting the organism for a sufficient time with a sufficient concentration of the composition of the invention, suitable compositions being those previously generically and specifically described.
  • the sufficient concentration of the composition is from about 0.1 to about 5 micrograms per milliliter of medium containing the organism.
  • the concentration required may be substantially higher, e.g. as much as 50 micrograms per milliliter.
  • the medium may be any solid or liquid.
  • the compositions may be used in or on the media as antiseptics, disinfectants, antimicrobial medicines or preservatives. It is to be understood that the above sufficient concentrations are those required to be in actual contact with the microorganism and substantially higher concentrations may be required in antiseptic preparations when penetration through a substance is required in order to contact the microorganism with the composition of the invention.
  • the sufficient time is the time required to inhibit the growth of the microorganism and may be the entire time of inhibition and when the microorganism is killed by the composition is usually from about 10 seconds to 30 minutes.
  • compositions may be used as additives to soaps, deodorants and sterilizing solutions to enhance or provide antimicrobial properties to these products.
  • Microorganism as used herein includes any microorganism whose growth can be inhibited by the compositions of the invention, i.e. a sensitive microorganism. Such microorganisms include almost all bacteria, especially gram-positive bacteria and are also believed to include many fungi. It is also possible that some other protists and perhaps even some viruses are included.
  • compositions in accordance with the invention are prepared by reacting a lower alkyl salicylic acid with a substitutted aniline to form the 5-alkylsalicyl- anilide.
  • the alkyl salicylic acids are prepared by known means, e.g. by Friedel-Crafts acylation of a lower alkyl salicylate with the appropriate acyl chloride (acid chloride) in the presence of a Lewis acid such as aluminum chloride followed by reduction and hydrolysis to form the alkyl salicylic acid. More specifically the synthesis of the compositions in accordance with the invention is believed to follow the following reaction path: R a is lower alkyl and is usually methyl.
  • Lower alkyl as used throughout this specification means alkyl of from 1 through 4 carbon atoms.
  • R - is AmR-. AmR is as previously described.
  • R y is R x -CH 2 where R x is the same as R but with less terminal n-carbon atom..
  • a reaction solvent is used to form the 5-acylsalicylic acid or ester.
  • a preferred reaction solvent is carbon disulfide.
  • Anhydrous aluminum chloride or other Lewis acid is added to the carbon disulfide and the mixture is cooled, e.g. with ice.
  • a solution of the alkyl salicylate, e.g. methyl salicylate, and acyl chloride in carbon disulfide or other reaction solvent is then slowly added and the temperature is maintained below about 10 degrees C.
  • the reaction mass is poured into ice water and the mixture is then extracted with a suitable solvent such a 2 ether, washed, dried over anhydrous sodium sulfate and evaporated in a vacuum.
  • the residue is dissolved in a suitable solvent such as ethanol and treated with a solution of an alkali metal hydroxide, e.g. 2N NaOH solution. After heating to a temperature of between about 80 and 12C degrees C, e.g. on a steam bath,. the mass is cooled and acidified with a suitable acid such as HC1 to pH of about 1 to precipitate the product. Recrystallization from ethanol gives purified 5-acylsalicylic acid.
  • a suitable solvent such as ethanol and treated with a solution of an alkali metal hydroxide, e.g. 2N NaOH solution.
  • a suitable acid such as HC1 to pH of about 1
  • the 5-acylsalicylic acid or ester is then reduced by known meams to form the corresponding 5-alkylsalicylic acid or ester, e.g. with amalgamated zinc and hydrochloric acid. If the ester is formed it is then hydrolized to form the acid.
  • 5-alkylsalicylic acid is reacted with the appropriate substituted aniline, e.g. p-nitro aniline, in a suitable reaction solvent such as chlorobenzene.
  • a suitable reaction solvent such as chlorobenzene.
  • the 5-alkylsalicylic acid is pre-reacted with phosphorus trichloride in the solvent at a suitable temperature, e.g. between about 55 and 80 degrees C.
  • the reaction time is usually between about one and about five hours.
  • the solution is then cooled and the appropriate substituted aniline, e.g. nitroaniline is then added and the solution is again heated to the suitable temperature, e.g. between 55 and 80 degrees as previously described for from about one to five hours and then is refluxed until the reaction is complete, e.g. for 24 hours.
  • the solvent is then removed in a vacuum and the residue is purified by recrystallization from a mixture of a suitable solvent such as a mixture of ethanol and water.
  • the resulting product is
  • a one-liter three-neck flask is fitted with a 250 ml dropping funnel, a mechanical overhead stirrer, and a condenser with a drying tube.
  • a mixture of anhydrous aluminium chloride (120 g., 0.9 moles) and carbon disulfide (250 ml) is placed in the flask and cooled to 0-5 degrees C with an ice bath.
  • a solution of methylsalicylate (45.6 g., 0.3 mole) and n-hexanoyl chloride (81.4 g., 0.6 mole) in carbon disulfide (50 ml) is then added through the dropping funnel over the course of three hours while maintaining the temperature of the raction mixture below 10 degrees C.
  • the reaction mixture is then allowed to warm to room temperature and stirring is continued for 24 hours.
  • the mixture is then poured slowly onto cracked ice (500 g.) and the resulting slurry is stirred until the ice melts.
  • the slurry is then extracted with four 50 ml portions of diethyl ether and the combined ether extracts are washed with water and dried over anhydrous sodium sulfate. Any remaining liquid is removed by evaporation in a vacuum.
  • the resulting product is found to be n-hexanoyl methyl salicylate in a yield of 77% with a melting point of 48-49 0 .
  • the LD 50 for S4-F by the single dose oral route is greater that 2500 mg/kg in female Osborne-Mendel white rats.
  • compositions of the invention manufactured essentially in accordance with the general process previously described are tested for antimicrobial activity against Actinomyces viscosus (A.vis), by introducing various concentrations of the compound to be tested into growth medium inoculated with the microorganism to determine the minimum concentration which will completely inhibit growth.
  • the results, in comparison with tribromsalan (TBS) of the prior art, are set forth in Table 1.
  • Example 6 The procedure of Example 6 is repeated except that the prior art composition chlorhexidine is included for comparison.
  • S4-F 5-n-butyl-3'-trifluoromethylsalicylanilide
  • bovine mandibles obtained immediately after slaughter, are cut into 4 x 8 mm slabs and sterilized in a 0.15 M NaCl solution buffered at a pH of 7.5 with 0.02 M sodium phosphate (PBS soln. ) Before use the slabs are coated with sterile saliva and then rinsed twice in sterile PBS. The slabs are then placed in small plastic petri dishes containing various concentrations of the compositions to be tested.
  • the test solution used is a solution of the composition in a mixture of 20% by volume of ethanol, 40% by volume of propylene glycol and 40% by volume of a pH 8 aqueous buffer solution containing mono and di sodium phosphates.
  • each slab is placed in a 10 x 75 mm cotton stoppered glass culture tube containing 1 ml of sucrose-broth culture medium which is then innoculated- with a 24 hour culture of A.viscosis standardized to an optical density (OD) 540 of 0.75. 50 / ul of the inoculation medium is used.
  • OD optical density
  • A.viscosus is incubated under aerobic conditions. After incubation for about 24 hours the nonadherent organisms are removed and the tube is rinsed twice with 0.5 ml of PBS and the washings combined with the nonadherent organisms.
  • the tooth slabs are then transferred to 1 ml of 0.1 N NaOH and 1 ml of 0.1 N NaOH is also added to the glass culture tubes.
  • the slabs and tubes are then sonically agitated, if necessary to suspend the adherent organisms.
  • the optical density of each of the three fractions is then measured on a spectophotometer.
  • the tests are repeated with varying concentrations of the compositions being tested until growth inhibition curves can be developed.
  • the 50% growth inhibition dosages (ID 50 ) are then determined with a reliability of + or - 80% or better. The results are set forth in Table 1.
  • S4-F a compound of the present invention
  • S4-F is comparable to commercial compounds tested in inhibition of the growth of A.viscosis plaques.
  • Much higher concentrations of S4-F are required to show the same preventative effect against plaque formation in the same test, using S.mutans as the organism, incubated under anaerobic conditions.
  • S4-F did not have a strong effect against established A.viscosis plaques in a different test. It is believed that the lower effect against established plaques is due to poor penetration into the plaque layer.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Birds (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

The composition comprises certain 5-Alkylsalicylanilides and more particularly comprises the compounds encompassed by the following generic formula:
Figure imga0001
where Z is a substitutea phenyl ring of from 6 to 30 carbon atoms including substituents, and R is a substituted or unsubstituted n-alkyl or phenyl group of from 4 to 30 carbon atoms including substituents.
The preferred compositions of the invention have a partition coefficient greater than 4 and the substituted moieties in the phenyl nng of the Z group have a combined overall electron withdrawing effect on the phenyl ring of the Z group.
The method of the invention comprises contacting a microorganism affected by the above composition with a sufficient concentration of the above composition for a sufficient time to inhibit the growth of the microorganism.
The above compositions are effective antiseptics against a wide range of microorganisms, especially bacteria, and the compositions surprisingly are effective against microorganisms prevalent in dental plaque.

Description

  • This invention relates to compositions and methods for killing or controlling the growth of microorganisms and more particularly relates to certain substituted salicylamide compositions having anti-bacterial activity which are particularly useful in controlling the growth of microorganisms related to dental plaques and associated diseases.
  • Historically compositions and methods have been sought for killing and controlling the growth of microorganisms, particularly those related to disease. The compositions which have been discovered for this purpose all have had one or more disadvantages. For example, the compositions have not been effective against all undesirable microorganisms such as disease causing bacteria, have permitted certain microorganisms to develop an immunity or tolerance for the composition, have been more toxic than desirable, have caused allergic reactions in the host, or have been expensive and difficult to manufacture or purify.
  • These disadvantages have been particularly noticeable in compositions used to control the growth of bacteria related to dental plaques and associated diseases. Prior art compositions used for this purpose are either insufficiently effective, are too toxic or both. Toxic as used here in means that the composition causes damage to an organism, especially a human, which uses the composition to control the growth of an undesired microorganism whether the composition is applied topically or otherwise.
  • Many compositions formerly and even currently in use as oral antiseptics, and for that matter many antiseptics for other uses, contain large quantities of chlorine or bromine, often attached to a phenyl amine ring. In general such aromatic amine chlorinated and brominated compounds are to be avoided due to toxicity and sometimes carcinogenicity often associated with this type of compound. Furthermore such compounds which have low enough toxicity to be used as oral antiseptics are usually not sufficiently effective at low concentrations to treat dental plaques and associated diseases.
  • An example of a compound which contains chlorine attached to a phenyl amine ring which is or has been used as an oral antiseptic is chlorhexidine. Another compound which has been used is tribromsalan a brominated salicylanilide. This compound is effective but still is not as effective as desirable in killing or sufficiently inhibiting the growth of plaque causing organisms at concentrations as low as desired.
  • Compounds which are used as oral antiseptics which contain chlorine or bromine but not in a phenyl ring are cetylpyridinium chloride and domiphen bromide. These compounds are also insufficiently effective in controlling microorganisms associated with dental plaque, especially in dentifrice compositions in which these compounds often become deactivated. Other antiseptics which contain chlorine attached to a phenyl ring but are not generally used in oral antiseptics are hexachlorophene and trichlocarban. A non-halogenated oral antiseptic is hexylresorcinal. Hexylresorcinal is insufficiently effective against plaque forming organisms and in addition has a toxicity which is higher than desired. There are many other antiseptics but most have toxicities which are too high, especially for oral use.
  • Halogenated salicylanilides have been studied as possible antiseptic compounds; however most halogenated salicylanilides have now been banned by the United States Food and Drug Administration from certain over-the counter-products. This ban is due to adverse effects resulting from the use of such products. For example tetrachlorosalicylanilide has been shown to produce allergic reactions in man and certain other hologenated salicylanilides have been reported to produce photo-allergic reactions.
  • It has been reported that certain tertiary butyl substituted salicylanilides are bactericides against the bacterium Staphylococoup aureus. To the time of the present invention it is not known what additional microorganisms might be affected by this compound and there is no indication that it might be effective against the traditionally difficult bacteria involved in dental plaques and associated diseases. (Japanese Patent 75,129,738 Oct 14, 1975).
  • There is therefore a need for an effective non-toxic antiseptic for general purpose use which may be but is preferably not halogenated with chlorine or bromine and there is definitely a need for a non-toxic antiseptic which is effective against the microorganisms associated with dental plaques and associated diseases.
  • In accordance with the present invention there is provided a novel composition which may be but is not necessarily halogenated with fluorine, chlorine or bromine and which is an effective antiseptic with low toxicity in its preferred forms and which very surprisingly in its preferred forms is very effective against organisms associated with dental plaques, with forms of caries, with periodontal diseases such as gingivitis and with other oral infections. In general the compositions are believed to be especially effective against gram-positive bacteria.
  • The compositions comprise certain 5-Alkylsalicylanilides and more particularly comprise the compounds encompassed by the following generic formula:
    Figure imgb0001
  • where Z is a substituted phenyl ring of from 6 to 30 carbon atoms including substituents, and R is a substituted or unsubstituted n-alkyl or phenyl group of from 4 to 30 carbon atoms including substitutents.
  • The preferred compositions of the invention have a partition coefficient greater than 4 and the substituted moieties in the phenyl ring of the Z group have a combined overall electron withdrawing effect on the phenyl ring of the Z group.
  • The above compositions are effective antiseptics against a wide range of bacteria and the preferred compositions surprisingly are especially effective against a prevalent microorganism in dental plaque, Actinomyces viscosus(A.vis.), and in addition are effective against some (but not necessarily all) other organisms associated with periodontal diseases often including Actinomyces naeslundii (A.naes.), Streptococcus mutans (S.mut.), Actinomyces israelii (A.isra.), Bacteroides melan- inoRenicus intermedius (B.mel.int.), and Streptoccus sanguis (S.sang).
  • The invention further comprises a method for inhibiting the growth of microorganisms by exposing a microorganisms whose growth is affected by the composition of the invention to a sufficient concentration of the composition to inhibit growth.
  • As previously mentioned, the present invention is concerned with certain antiseptic compositions and particularly certain 5 alkyl derivatives of salicylanilides. These compositions all have at least some antiseptic properties and the preferred compositions have excellent antiseptic properties especially against certain microorganisms associated with dental plaques and associated oral diseases. Furthermore many of these compositions are characterised by having low toxicity to mammals. Additionally the invention includes the method for controlling the growth of microorganisms by contacting sensitive microorganisms with a composition of the invention for a sufficient time to kill or inhibit the growth or reproduction of the organisms. The contact of the microorganism with the composition may be accomplished in either in vivo or in vitro environments.
  • The compositions comprise certain 5-Alkylsalicylanilides and more particularly comprise the compounds encompassed by the following generic formula:
    Figure imgb0002
  • where Z is a substituted phenyl ring of from 6 to 30 carbon atoms including substituents, and R is a substituted or unsubstituted n-alkyl or phenyl group of from 4 to 30 carbon atoms including substituents.
  • The preferred compositions of the invention have a partition coefficient greater than 4 and the substituted moieties in the phenyl ring of the Z group have a combined overall electron withdrawing effect on the phenyl ring of the Z group.
  • "Partition coefficient" of a composition as used herein is the log 10 P where P is the ratio of the concentration of the composition in octanol to the concentration of the composition in water in a two phase octanol-water system. A partition coefficient of 4 therefore means that the ratio of the concentration of the composition in octanol to the concentration of the composition in water is 104 or 10,000 to 1. The partition coefficient is a measure of the Iipophylic character of the compound. The preferred compositions of the invention are lipophylic as indicated by a partition coefficient of greater than 4. The partition coefficient is however usually less than 10.
  • "Substituted" as used herein means that the organic composition or radical to which the term is applied is:
    • a) made unsaturated by the elimination of one or more elements or radicals; or
    • b) at least one hydrogen in the compound or radical is replaced with a moiety (Y) containing one or more carbon, oxygen, sulfur, nitrogen or halogen atoms; or
    • c) both a) and b).
  • Moieties which may replace hydrogen, as previously described, which contain only carbon and hydrogen are all hydrocarbon moieties including alkyl, alkenyl, alkynyl, alkyldienyl, cycloalkyl, phenyl, alkylphenyl, naphthyl, anthryl, phenanthryl, fluoryl, steroid groups, and combinations of these groups with each other and with polyvalent hydrocarbon groups such as alkylene, alkylidene and alkylidyne groups. Specific examples of such groups are:
    • -CH3, -CHCH3CH3, -(CH2)8CH3, -CH2-C-CH, -CH-CH-CH=CH2,
    • -HC-(CH2)4-CH2, -ØCH3' -ØCH2Ø, -ø, and -ø-ø.
  • Moieties containing oxygen which may replace hydrogen as previously described include hydroxy, acyl or keto, ether, epoxy, carboxy, and ester containing groups. Specific examples of such oxygen containing groups are O -CH2OH, - CCH3CH3OH, -CH2COOH, -C-(CH2)8CH3, -OCH2CH3, =0, -OH, -CH2-O-CH2CH3, -CH2-O-(CH2)2-OH,
    Figure imgb0003
    , -CH2CH2COOH, -ØOH, -ØOCH2CH3, -ØCH2OH, -ØOCH2CH3,
    Figure imgb0004
    and -CH2CH2COOH.
  • Examples of moieties containing sulfur are the sulfur containing acids and acid ester groups, thioether groups, mercapto groups and thioketo groups. Specific examples of such groups are: -SCH2CH3, -CH2S(CH2)4CH3, -SO3CH2CH3, -SO2CH2CH3, -CH2COSH, -SH,
    Figure imgb0005
  • Examples of moieties containing nitrogen are amino groups, the nitro group, azo groups, ammonium groups, amide groups, azido groups, isocyanate groups, cyano groups and nitrile groups. Specific examples of such groups are:
    • -NHCH3, -NH2, -NH3 +, -CH2CONH2, -CH2CON3, -CH2CH2CH=NOH, -CN,
    • -CHCH3CH2NCO, -CH2SCO,
      Figure imgb0006
      -ØN=NØOH, and =N.
  • Examples of moieties containing halogen are chloro, bromc; fluoro, iodo groups and any of the moieties previously described where a hydrogen or a pendant alkyl group is substituted by a halo group to form a stable substituted moiety.
  • Specific examples of halogen containing moieties are:
    • -(CH2)3COCl, -ØF5' -ØCl, -CF3, and -CH2ØBr.
  • It is understood that any of the above moieties can be substituted into each other in either a monovalent substitution or by loss of hydrogen in a polyvalent substitution to form another monovalent moiety which can replace hydrogen in the organic compound or radical. "Lower alkyl" as used herein means an alkyl group of from 1 through 5 carbon atoms. "-Ø" as used herein represents a phenyl ring.
  • A generic formula which includes many of the preferrred compositions of the invention is:
    Figure imgb0007
  • where-R- is a saturated or unsaturated, halogenated or unhalogenated n-alkylene or phenylene group containing 4 through 20 carbon atoms. -R- may be cycloalkylene, e.g.cyclohexylene. Examples of preferred -R- groups are: -0-, -(CII2)4-, -(CH2)6-' and -(CH2)8-. Other -R- groups are -(CH2)6(CCl2)-,-(CF2)6-,and -(CCl2)8-. It is apparent that the foregoing are only examples of possible -R- groups.
  • A is independently at each occurrence -H, -OH, -halogen, lower alkoxy, lower alkyl, -SH, thioalkyl, phenyl,phenoxy, -NH2, lower amino or lower acyl group. A is most preferably methyl (-CH3) or -H. In general when A contains oxygen or another group or element which tends to increase the hydrophylic nature of the R group, additional lipophylic groups or elements must be present so that the overall hydrophylic-lipophylic balance of the R group decidely favors solubility in fats or oils. As used herein lipophylic means the tendency to be attracted to fats or oils and as is well known hydrophylic means to be attracted to water. The R group should in fact be sufficiently lipophylic to give an overall lipophylic character to the composition, i.e. a partition coefficient greater than 4.
  • m is an integer of from 1 through 3 and in the preferred embodiments of the invention is usually 1 since pendant groups from the -R - moiety usually do not add greatly to the antimicrobial character of the compounds and even if they do the same pendant groups often can increase toxicity to mammals. Pendant groups which are hydrophylic in particular have been found to reduce anti-microbial activity unless more lipophylic groups are added to the R moiety to offset them.
  • Y is independently at each occurrence -H, lower alkyl, halogenated lower alkyl, -N02, -CN, -halogen, lower acyl, -S02R", or -S03R" where R" is lower alkyl or halogenated lower alkyl, provided that at least one of Y is not H or lower alkyl. Generally Y is not chlorine or bromine when applied to humans due to the increased toxicity or carcinogenicity often associated with halogenated phenyl rings. Halogen has however been found to sometimes even further increase antimicrobial activity and thus is nevertheless sometimes used especially when the compound is used only in in-vitro environments. Halogen, especially fluorine, can be used with benefit and very little or no increase in toxicity when the halogen is attached to an aliphatic carbon atom instead of directly to the phenyl ring. An example of a very good Y group is -CF3. In general all good Y groups are electron withdrawing groups and desirably are not strongly hydrophylic or water solubilizing groups. A particularly good Y group is -N02 especially when it is in the 4' position on the phenyl ring. Another very good Y group is -1' especially when located in all of the Y positions on the phenyl ring.
  • Examples of compounds especially suitable for use in accordance with the invention are those compounds wherein A is -H, m=1, Y is -NO2, -Br or -Cl in the 4' position or -CF3 in the 3', 4' or 5' position of -F in all Y positions. Examples of other compounds highly suitable for use in accordance with the invention are those compounds wherein m is 1 or 2, at least one A is not -H and Y is independently at each occurrence -H, -halogen, -N02, -CN, halogenated lower alkyl, -CHO, or lower acyl. -R- may be cycloalkylene as previously discussed.
  • Examples of specific compounds in accordance with the invention are the compounds having the formula:
    Figure imgb0008
    • where R is CH3 (CH2)3- and Y is -NO2;
    • where R is CH3(CH2)5- and Y is -NO2;
    • where R is CH3(CH2)7- and Y is -NO2;
    • where R is CH3(CH2)3- and Y is -Br;
    • where R is CH3(CH2)5- and Y is -Br;
    • where R is CH3(CH2)7- and Y is -Br;
    • where R is CH3(CH2)3- and Y is -CF3;
    • where R is CH3(CH2)5- and Y is -CF3;
    • where R is CH3(CH2)7- and Y is -CF3.
  • More examples of preferred compounds in accordance with the invention are those compounds having the formula:
    Figure imgb0009
    • where R is CH3(CH2)3- and Y is -CF3;
    • where R is CH3(CH2)5 - and Y is -CF3; and
    • where R is CH3(CH2)7 - and Y is -CF3.
  • Additional examples of preferred compounds are those compounds having the formula:
    Figure imgb0010
    • where R is CH3(CH2)3-;
    • where R is CH3(CH2)5-; and
    • where R is CH3(CH2)7-.
  • The method in accordance with the present invention for inhibiting the growth of microorganisms and especially bacterial organisms comprises contacting the organism for a sufficient time with a sufficient concentration of the composition of the invention, suitable compositions being those previously generically and specifically described. In general the sufficient concentration of the composition is from about 0.1 to about 5 micrograms per milliliter of medium containing the organism. For very difficult microorganisms, e.g. fusobacteria, the concentration required may be substantially higher, e.g. as much as 50 micrograms per milliliter. The medium may be any solid or liquid. Examples of media within or upon which the composition may be used are organic tissue, dental surfaces, floors, walls, hardware and implements in general, paints, textiles, leather, synthetic resins and in tne future perhaps foods and medicines and other ingestible substances. The compositions may be used in or on the media as antiseptics, disinfectants, antimicrobial medicines or preservatives. It is to be understood that the above sufficient concentrations are those required to be in actual contact with the microorganism and substantially higher concentrations may be required in antiseptic preparations when penetration through a substance is required in order to contact the microorganism with the composition of the invention. The sufficient time is the time required to inhibit the growth of the microorganism and may be the entire time of inhibition and when the microorganism is killed by the composition is usually from about 10 seconds to 30 minutes.
  • The compositions may be used as additives to soaps, deodorants and sterilizing solutions to enhance or provide antimicrobial properties to these products.
  • Microorganism as used herein includes any microorganism whose growth can be inhibited by the compositions of the invention, i.e. a sensitive microorganism. Such microorganisms include almost all bacteria, especially gram-positive bacteria and are also believed to include many fungi. It is also possible that some other protists and perhaps even some viruses are included.
  • In general the compositions in accordance with the invention are prepared by reacting a lower alkyl salicylic acid with a substitutted aniline to form the 5-alkylsalicyl- anilide. The alkyl salicylic acids are prepared by known means, e.g. by Friedel-Crafts acylation of a lower alkyl salicylate with the appropriate acyl chloride (acid chloride) in the presence of a Lewis acid such as aluminum chloride followed by reduction and hydrolysis to form the alkyl salicylic acid. More specifically the synthesis of the compositions in accordance with the invention is believed to follow the following reaction path:
    Figure imgb0011
    Ra is lower alkyl and is usually methyl. Lower alkyl as used throughout this specification means alkyl of from 1 through 4 carbon atoms. R - is AmR-. AmR is as previously described. Ry is Rx-CH2 where Rx is the same as R but with less terminal n-carbon atom..
  • As a usual procedure, a reaction solvent is used to form the 5-acylsalicylic acid or ester. A preferred reaction solvent is carbon disulfide. Anhydrous aluminum chloride or other Lewis acid is added to the carbon disulfide and the mixture is cooled, e.g. with ice. A solution of the alkyl salicylate, e.g. methyl salicylate, and acyl chloride in carbon disulfide or other reaction solvent is then slowly added and the temperature is maintained below about 10 degrees C. After complete reaction which may take as long as 24 hours, the reaction mass is poured into ice water and the mixture is then extracted with a suitable solvent such a2 ether, washed, dried over anhydrous sodium sulfate and evaporated in a vacuum. The residue is dissolved in a suitable solvent such as ethanol and treated with a solution of an alkali metal hydroxide, e.g. 2N NaOH solution. After heating to a temperature of between about 80 and 12C degrees C, e.g. on a steam bath,. the mass is cooled and acidified with a suitable acid such as HC1 to pH of about 1 to precipitate the product. Recrystallization from ethanol gives purified 5-acylsalicylic acid.
  • The 5-acylsalicylic acid or ester is then reduced by known meams to form the corresponding 5-alkylsalicylic acid or ester, e.g. with amalgamated zinc and hydrochloric acid. If the ester is formed it is then hydrolized to form the acid.
  • 5-alkylsalicylic acid is reacted with the appropriate substituted aniline, e.g. p-nitro aniline, in a suitable reaction solvent such as chlorobenzene. Desirably the 5-alkylsalicylic acid is pre-reacted with phosphorus trichloride in the solvent at a suitable temperature, e.g. between about 55 and 80 degrees C. The reaction time is usually between about one and about five hours. The solution is then cooled and the appropriate substituted aniline, e.g. nitroaniline is then added and the solution is again heated to the suitable temperature, e.g. between 55 and 80 degrees as previously described for from about one to five hours and then is refluxed until the reaction is complete, e.g. for 24 hours. The solvent is then removed in a vacuum and the residue is purified by recrystallization from a mixture of a suitable solvent such as a mixture of ethanol and water. The resulting product is the 5-alkylsalicylic acid of the invention.
  • The following examples serve to illustrate and not limit the present invention.
    • EXAMPLE 1
  • Preparation of 5-n-hexanoylsalicylic acid.
  • A one-liter three-neck flask is fitted with a 250 ml dropping funnel, a mechanical overhead stirrer, and a condenser with a drying tube. A mixture of anhydrous aluminium chloride (120 g., 0.9 moles) and carbon disulfide (250 ml) is placed in the flask and cooled to 0-5 degrees C with an ice bath. A solution of methylsalicylate (45.6 g., 0.3 mole) and n-hexanoyl chloride (81.4 g., 0.6 mole) in carbon disulfide (50 ml) is then added through the dropping funnel over the course of three hours while maintaining the temperature of the raction mixture below 10 degrees C. The reaction mixture is then allowed to warm to room temperature and stirring is continued for 24 hours. The mixture is then poured slowly onto cracked ice (500 g.) and the resulting slurry is stirred until the ice melts. The slurry is then extracted with four 50 ml portions of diethyl ether and the combined ether extracts are washed with water and dried over anhydrous sodium sulfate. Any remaining liquid is removed by evaporation in a vacuum. The resulting product is found to be n-hexanoyl methyl salicylate in a yield of 77% with a melting point of 48-490.
    • EXAMPLE 2
  • 100 grams of particulate zinc is stirred in a 500 ml flask with a solution of 10 grams of mercuric chloride and 5 mls of concentrated hydrochloric acid in 100 mls of water. The liquid is then decanted and the resulting amalgamated zinc is washed with water. 50 grams of 5-hexanoyl methyl salicylatc, 150 mls of concentrated hydrochloric acid and 60 mls of water are then added to the amalgamated zinc and the mixture is refluxed for 24 hours with an additional 40 mls of hydrochloric acid being added every 6 hours. The solution is then cooled and poured through a separatory funnel and extracted with ether. The extracts are then dried. The residue is dissolved in ethanol and saponified (hydrolysed) by adding the solution to 2N sodium hydroxide solution which is then heated on a steam bath for 12 hours. The solution is then cooled and acidified with concentrated hydrochloric acid to pH 1 which results in a precipitate which is collected in a Buchner funnel. Recrystallization from ethanol-water gives 36.5 grams of 5-n-hexylsalicylic acid, mp 83-84°C.
    • EXAMPLE 3
  • Preparation of 5-n-hexyl-4'nicrosalicylanilide abreviated SAN-6.
  • In a 100 ml round-bottom flask fitted with a condenser and drying tube is placed 5-n-hexylsalicylic acid (3 grams), dry chlorobenzene (50 ml), and phosphorus trichloride (0.6 ml). The mixture is then stirred by means of a magnetic stirring bar while the mixture is heated to 60°C for three hours. The resulting solution is cooled to room temperature and 1.86 grams of p-nitroaniline is added. The mixture is then heated to 60°C for three hours, with stirring, and then refluxed for 24 hours. The solvent is removed by vacuum vaporization and the residue is recrystallized from ethanol-water. The crystalline product is triturated with concentrated hydrochloric acid, collected and washed with water. Recrystallization from ethanol-water gives 2.6 grams of 5-n-hexyl-4'-nitrosalicylanilide, mp 154-155°c.
    • EXAMPLE 4
  • Acute oral toxicity of S4-F.
  • Sixteen female Sprague-Dawley white rats averaging 250 grams in weight were fasted overnight and divided into four groups of four animals each. In one group each animal received, by gavage tube, 2.5 ml of an aqueous solution of 1% methylcellulose, the drug delivery vehicle. This group was the control group. The remaining three groups received doses of 75,750, and 2500 mg/kg of 5-n-butyl-3'-trifluoro- methylsalicylanilide (S4-F) in 2.5 ml 1% aqueous methylcellulose suspension, respectively.
  • After two weeks following this single does, nc animals had died. All animals in the various groups showed weight gain after one and two weeks.
  • From this experiment it can be concluded that the LD50 for S4-F by the single dose oral route is greater that 2500 mg/kg in female Osborne-Mendel white rats.
    • EXAMPLE 5
  • Effectiveness of Certain Compositions of the Invention Against Certain Bacteria.
  • Several compositions of the invention manufactured essentially in accordance with the general process previously described are tested for antimicrobial activity against Actinomyces viscosus (A.vis), by introducing various concentrations of the compound to be tested into growth medium inoculated with the microorganism to determine the minimum concentration which will completely inhibit growth. The results, in comparison with tribromsalan (TBS) of the prior art, are set forth in Table 1.
    Figure imgb0012
    • EXAMPLE 6
  • The procedure of example 5 is followd except that various other organisms are used. The results are set forth in Table 2.
    Figure imgb0013
    • EXAMPLE 7
  • The procedure of Example 6 is repeated except that the prior art composition chlorhexidine is included for comparison.
    • Organism - Streptococcus mutans
  • Figure imgb0014
    • EXAMPLE 8
  • Plaque growth inhibition.
  • 5-n-butyl-3'-trifluoromethylsalicylanilide (S4-F) is tested in vitro for plaque inhibition in comparison with prior art compounds. The test used is set forth in detail in Comparison of Anti-plaque Agents Using an In Vitro Reflecting Oral Conditions by R T Evans et al, Journal of Dental Research, June 1977.
  • In summary, bovine mandibles, obtained immediately after slaughter, are cut into 4 x 8 mm slabs and sterilized in a 0.15 M NaCl solution buffered at a pH of 7.5 with 0.02 M sodium phosphate (PBS soln. ) Before use the slabs are coated with sterile saliva and then rinsed twice in sterile PBS. The slabs are then placed in small plastic petri dishes containing various concentrations of the compositions to be tested. The test solution used is a solution of the composition in a mixture of 20% by volume of ethanol, 40% by volume of propylene glycol and 40% by volume of a pH 8 aqueous buffer solution containing mono and di sodium phosphates. The slabs are left in the solution of the composition for two minutes and then rinsed in sterile PBS solution. After rinsing, each slab is placed in a 10 x 75 mm cotton stoppered glass culture tube containing 1 ml of sucrose-broth culture medium which is then innoculated- with a 24 hour culture of A.viscosis standardized to an optical density (OD)540 of 0.75. 50 /ul of the inoculation medium is used. A.viscosus is incubated under aerobic conditions. After incubation for about 24 hours the nonadherent organisms are removed and the tube is rinsed twice with 0.5 ml of PBS and the washings combined with the nonadherent organisms.
  • The tooth slabs are then transferred to 1 ml of 0.1 N NaOH and 1 ml of 0.1 N NaOH is also added to the glass culture tubes. The slabs and tubes are then sonically agitated, if necessary to suspend the adherent organisms. The optical density of each of the three fractions is then measured on a spectophotometer. The tests are repeated with varying concentrations of the compositions being tested until growth inhibition curves can be developed. The 50% growth inhibition dosages (ID50) are then determined with a reliability of + or - 80% or better. The results are set forth in Table 1.
    Figure imgb0015
  • As can be seen from the foregoing table, S4-F, a compound of the present invention, is comparable to commercial compounds tested in inhibition of the growth of A.viscosis plaques. Much higher concentrations of S4-F are required to show the same preventative effect against plaque formation in the same test, using S.mutans as the organism, incubated under anaerobic conditions. S4-F did not have a strong effect against established A.viscosis plaques in a different test. It is believed that the lower effect against established plaques is due to poor penetration into the plaque layer.

Claims (39)

1. A composition having the formula:
Figure imgb0016
where Z is a substituted phenyl ring of from 6 to 30 carbon atoms including substituents, and R is a substituted or unsubstituted n-alkyl or phenyl group of from 4 to 30 carbon atoms including substituents.
2. A composition having the formula
Figure imgb0017
where Z is a substituted phenyl ring of from 6 to 30 carbon atoms including substituents, and R is a substituted or unsubstituted n-alkyl or phenyl group of from 4 to 30 carbon atoms including substituents, said composition having a partition coefficient greater than 4 and the substituted moieties in the phenyl ring of the Z group having a combined overall electron withdrawing effect on the phenyl ring of the Z group.
3. A composition having the formula:
Figure imgb0018
where-R-is a saturated or unsaturated, halogenated cr unhalogenated n-alkylene, cycloalkylene or phenylene group containing 4 through 20 carbon atoms, A is independently at each occurrence -H, -OH, -halogen, lower alkoxy, lower alkyl, -SH, thioalkyl, phenyl, phenoxy, -NH2, lower amino or lower acyl group; m is an integer of 1 through 3 and Y is independently at each occurrence -H, lower alkyl, halogenated lower alkyl, -N02, -CN, -halogen, lower acyl, -SO2R", or -S03R" where R" is lower alkyl or halogenated lower alkyl of up to 10 carbon atoms, provided that at least one of Y is not H or lower alkyl.
4. The composition of Claim 3 wherein A is -H, m=1, and at least one Y is -NO2, -Br, -Cl, -F, or CF3.
5. A composition of the formula
Figure imgb0019
where R is CH3(CH2)3- and Y is -NO2.
6. A composition of the formula:
Figure imgb0020
where R is CH3(CH2)5 -and Y is -NO2.
7. A compostion of the formula:
Figure imgb0021
where R is CH3(CH2)7 - and Y is -NO2.
8. A composition of the formula:
Figure imgb0022
where R is CH3(CH2)3 - and Y is -Br.
9. A composition of the formula:
Figure imgb0023
where R is CH3(CH2)5- and Y is -Br.
10. A composition of the formula:
Figure imgb0024
where R is CH3(CH2)3 - and Y is -CF3.
11. A composition of the formula:
Figure imgb0025
where R is CH3(CH2)5- and Y is CF 3
12. A composition of the formula:
Figure imgb0026
where R is CH3(CH2)7 - and Y is -CF3.
13. A .composition of the formula:
Figure imgb0027
where R is CH3(CH2) 3-.
14. A composition of the formula:
Figure imgb0028
where R is CH3(CH2)5-.
15. A composition of the formula:
Figure imgb0029
where R is CH3(CH2)7-'
16. A composition of the formula:
Figure imgb0030
where R is CH3(CH2)3-.
17. A composition of the formula:
Figure imgb0031
where R is CH3(CH2)5-.
18. A composition of the formula:
Figure imgb0032
where R is CH3(CH2)7-.
19. The composition of Claim 3 wherein m is 1 or 2, at least one A is not -H and Y is independently at each occurrence -H, -halogen, -N02, -CN, halogenated lower alkyl, -CHO, or lower acyl.
20. A method for inhibiting the growth of microorganisms comprising contacting the organism for a sufficient time with a sufficient concentration of the composition of Claim 1.
21. The method of Claim 20 wherein the microorganism is a bacterial organism, the sufficient concentration is from about 0.1 to about 5 micrograms per milliliter of medium containing the organism and the sufficient time is the entire time of growth inhibition.
22. The method of Claim 20 wherein the microorganism is a bacterial organism, the sufficient concentration is from about 0.1 to about 50 micrograms per milliliter of medium containing the microorganism, the sufficient time is from 10 seconds to 30 minutes and the growth is inhibited by killing of the bacterial organisms.
23. The method of Claim 21 wherein the bacterial organism is A.viscosus, A.naeslundii S.mutans, B.mel.intermed., B.mel.asacch., S.sanguis, Staphylococcus aureus or mixtures thereof.
24. The method of Claim 22 wherein the bacterial organism is A.viscosus, A. naeslundii, S. mutans, B. mel.intermed., B.mel.asacch., S. sanguis, Staphylococcus aureus or mixtures thereof.
25. A method for inhibiting the growth of microorganisms comprising contacting the organism for a sufficient time with a sufficient concentration of the composition of Claim 2.
26. The method of Claim 25 wherein the microorganism is a bacterial organism, the sufficient concentration is from about 0.1 to about 5 micrograms per milliliter of medium containing the organism and the sufficient time is the entire time of growth inhibition.
27. The method of Claim 25 wherein the microorganism is a bacterial organism, the sufficient concentration is from about 0.1 to about 50 micrograms per milliliter of medium containing the microorganism, the sufficient time is from 10 seconds to 30 minutes and the growth is inhibited by killing of the bacterial organisms.
28. The method of Claim 26 wherein the bacterial organism is A.viscosus, A.naeslundii, S.mutans, B.mel. intermed., B.mel.asacch., S.sanguis, Staphylococcus aureus or mixtures thereof.
29. The method of Claim 27 wherein the bacterial organism is A.viscosus, A.naeslundii, S.mutans, B.mel.intermed., B.mel.asacch., S.sanguis, Staphylococcus aureus or mixtures thereof.
30. A method for inhibiting the growth of microorganisms comprising contacting the organism for a sufficient time with a sufficient concentration of the composition of Claim 3.
31. The method of Claim 30 wherein the microorganism is a bacterial organism, the sufficient concentration is from about 0.1 to about 5 micrograms per milliliter of medium containing the organism and the sufficient time is the entire time of growth inhibition.
32. The method of Claim 30 wherein the microorganism is a bacterial organism, the sufficient concentration is from about 0.1 to about 50 micrograms per milliliter of medium containing the microorganism, the sufficient time is from 10 seconds to 30 minutes and the growth is inhibited by killing of the bacterial organisms.
33. The method of Claim 31 wherein the bacterial organism is A.viscosus, A.naeslundii, S.mutans, B.mel.intermed., B.mel.asacch., S.sanguis, Staphylococcus aureus or mixtures thereof.
34. The method of Claim 32 wherein the bacterial organism is A.viscosus, A.maeslundii, S.mutans, B.mel.intermed., B.mel.asacch., S.sanguis, Staphylococcus aureus or mixtures thereof.
35. A method for inhibiting the growth of microorganisms comprising contacting the organism for a sufficient time with a sufficient concentration of the composition of Claim 4.
36. The method of Claim 35 wherein the microorganism is a bacterial organism, the sufficient concentration is from about 0.1 to about 5 micrograms per milliliter of medium containing the organism and the sufficient time is the entire time of growth inhibition.
37. The method of Claim 35 wherein the microorganism is a bacterial organism, the sufficieint concentration is from about 0.1 to about 50 micrograms per milliliter of medium containing the microorganism, the sufficient time is from 10 seconds to 30 minutes and the growth is inhibited by killing of the bacterial organisms.
38. The method of Claim 36 wherein the bacterial organism is A.viscosus, A.naeslundii, S.mutans, B.mel. intermed., B.mel.asacch., S.sanguis, Staphylococcus aureus or mixtures thereof.
39. The method of Claim 37 wherein the bacterial organism is A.viscosus, A.naeslundii, S.mutans, B.mel.intermed., B.mel.asacch., S.sanguis, Staphylococcus aureus or mixtures thereof.
EP81301586A 1980-04-14 1981-04-10 5-Alkylsalicylanilides derivatives and method for inhibiting the growth of microorganisms Expired EP0038192B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AT81301586T ATE8989T1 (en) 1980-04-14 1981-04-10 5-ALKYLSALICYLANILIDE DERIVATIVES AND METHODS OF INHIBITING THE GROWTH OF MICROORGANISMS.

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US140098 1980-04-14
US06/140,098 US4287191A (en) 1980-04-14 1980-04-14 Novel salicylanilides and microbiocidal compositions and uses thereof
US06/176,419 US4358443A (en) 1980-04-14 1980-08-08 Method and composition for controlling the growth of microorganisms
US176419 1998-10-21

Publications (3)

Publication Number Publication Date
EP0038192A1 true EP0038192A1 (en) 1981-10-21
EP0038192B1 EP0038192B1 (en) 1984-08-15
EP0038192B2 EP0038192B2 (en) 1989-12-27

Family

ID=26837870

Family Applications (1)

Application Number Title Priority Date Filing Date
EP81301586A Expired EP0038192B2 (en) 1980-04-14 1981-04-10 5-Alkylsalicylanilides derivatives and method for inhibiting the growth of microorganisms

Country Status (3)

Country Link
US (1) US4358443A (en)
EP (1) EP0038192B2 (en)
DE (1) DE3165507D1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0144204A3 (en) * 1983-12-05 1986-10-22 Unilever Plc Process for preparing salicylamide compounds
EP0143628A3 (en) * 1983-11-28 1986-10-22 Unilever Plc Process for preparing salicylamide compounds
GB2174906A (en) * 1985-05-07 1986-11-19 Oreal Topical compositions containing salicylic acid derivatives
EP0221211A1 (en) * 1983-08-24 1987-05-13 Unilever Plc Use of secondary amide compounds for the manufacture of medicaments for the treatment of dermatological inflammation
EP0223515A3 (en) * 1985-11-08 1987-12-16 Unilever Plc Oral compositions comprising salicylamides and zinc salts for the synergistic inhibition of dental plaque
EP1328507A4 (en) * 2000-10-02 2005-07-27 Univ New York State Res Found NAPHTHYLSALICYLANILIDES AS ANTIMICROBIAL AND ANTI-INFLAMMATORY AGENTS

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4742083A (en) * 1983-08-24 1988-05-03 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4725590A (en) * 1983-08-24 1988-02-16 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
US4659826A (en) * 1983-11-28 1987-04-21 Lever Brothers Company Synthesis of salicylamides with improved yield and purity
US4701527A (en) * 1983-12-05 1987-10-20 Lever Brothers Company Synthesis of salicylamides with improved reaction kinetics and improved effective yields
US4939132A (en) * 1985-04-15 1990-07-03 The Research Foundation Of State University Of New York Novel 5-alkylsulfonylsalicylanilides and microbiocidal compositions for controlling the growth of microorganisms
GB9117140D0 (en) * 1991-08-08 1991-09-25 Unilever Plc Treatment of periodontitis
US5958911A (en) * 1996-11-05 1999-09-28 The Research Foundation Of State University Of New York Method of relieving inflammation by using 5-alkylsulfonylsalicylanilides
US6117859A (en) * 1997-11-04 2000-09-12 The Research Foundation Of State University Of New York Method of relieving chronic inflammation by using 5-alkylsulfonylsalicylanilides
CA2363690C (en) 1999-03-25 2006-10-24 Boehringer Ingelheim (Canada) Ltd. Hsv primase inhibitors
US7319112B2 (en) * 2000-07-14 2008-01-15 The Procter & Gamble Co. Non-halogenated antibacterial agents and processes for making same
UA82827C2 (en) * 2000-12-18 2008-05-26 Inhibitors against the production and release of inflammatory cytokines
DE10222895A1 (en) * 2002-05-23 2003-12-11 Bosch Gmbh Robert High pressure accumulator for fuel injection systems with integrated pressure control valve
AU2003242131A1 (en) * 2002-06-05 2003-12-22 Institute Of Medicinal Molecular Design, Inc. Immunity-related protein kinase inhibitors
TW200410671A (en) * 2002-06-05 2004-07-01 Inst Med Molecular Design Inc Medicines for inhibiting the activation of AP-1
CN101103977A (en) * 2002-06-05 2008-01-16 株式会社医药分子设计研究所 Therapeutic agent for diabetes
CN1658855B (en) * 2002-06-06 2010-04-28 株式会社医药分子设计研究所 O-Substituted Hydroxyaryl Derivatives
CN1658872B (en) * 2002-06-06 2010-09-22 株式会社医药分子设计研究所 anti allergy medicine
EA010470B1 (en) * 2002-06-10 2008-08-29 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. NF-kappa B ACTIVATION INHIBITORS
EP1535610A4 (en) * 2002-06-10 2008-12-31 Inst Med Molecular Design Inc THERAPEUTIC AGENT TO TREAT CANCER
EA011707B1 (en) * 2002-06-11 2009-04-28 Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. Remedies for neurodegenerative diseases
AU2003244325A1 (en) * 2002-11-12 2004-06-03 Nok Corporation Rubber-like elastic part
JPWO2005007151A1 (en) * 2003-07-16 2006-08-31 株式会社医薬分子設計研究所 Skin pigmentation treatment
US7671058B2 (en) * 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
EP3967312A1 (en) 2014-09-12 2022-03-16 UNION therapeutics A/S Antibacterial use of halogenated salicylanilides
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE618213C (en) * 1934-03-14 1935-09-06 I G Farbenindustrie Akt Ges Process for the preparation of arylides of 4-oxydiphenyl-3-carboxylic acid
GB728098A (en) * 1952-03-05 1955-04-13 Geigy Ag J R Improvements relating to salicylanilides and their use
GB946029A (en) * 1961-04-17 1964-01-08 Gillette Co Salicylic acid derivatives and compositions containing them
US3377238A (en) * 1966-11-21 1968-04-09 Dow Chemical Co Method for controlling gastropods
GB1229669A (en) * 1967-10-06 1971-04-28
FR2234274A1 (en) * 1973-06-25 1975-01-17 Yoshitomi Pharmaceutical

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE524930A (en) * 1952-12-09
US3027301A (en) * 1959-03-16 1962-03-27 Us Vitamin Pharm Corp Therapeutic wound healing composition of hydroxypropylamides of hydroxybenzoic acids
NL134190C (en) * 1959-08-27
US3929879A (en) * 1960-09-19 1975-12-30 Ben Venue Lab Inc 3-Nitrohalosalicylanilides
FR1299134A (en) * 1961-06-09 1962-07-20 Germicides containing halogenated salicylic acid trifluoromethyl anilides
US3317583A (en) * 1964-01-13 1967-05-02 Upjohn Co Alkylcarbamates of cyanosalicylanilides
BE756232A (en) * 1969-09-16 1971-03-16 Hoechst Ag 3-ACYL-ALPHA-RESORCYLIC ACID ANILIDES AND THEIR PREPARATION
US3989826A (en) * 1972-05-12 1976-11-02 Ici Australia Limited Method of killing internal parasites using salicylanilides
US3888980A (en) * 1972-08-01 1975-06-10 Ferro Corp Antimicrobial compounds of 2', 5'+0 substituted nitroanilides of substituted nitrosalicylic acid for quadruped animals
US3917617A (en) * 1973-10-01 1975-11-04 Sharps Ass 1-{8 2,6-Dihydroxy-4-hydrocarbyl-benzoyl{9 polymethyleneimines and derivatives
GB1493375A (en) * 1974-09-20 1977-11-30 Ici Ltd Salicylanilide derivatives
JPS5439040A (en) * 1977-09-01 1979-03-24 Nippon Kayaku Co Ltd Novel 2-hydroxybenzamide derivatives and bactericides for the soil

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE618213C (en) * 1934-03-14 1935-09-06 I G Farbenindustrie Akt Ges Process for the preparation of arylides of 4-oxydiphenyl-3-carboxylic acid
GB728098A (en) * 1952-03-05 1955-04-13 Geigy Ag J R Improvements relating to salicylanilides and their use
GB946029A (en) * 1961-04-17 1964-01-08 Gillette Co Salicylic acid derivatives and compositions containing them
US3377238A (en) * 1966-11-21 1968-04-09 Dow Chemical Co Method for controlling gastropods
GB1229669A (en) * 1967-10-06 1971-04-28
FR2234274A1 (en) * 1973-06-25 1975-01-17 Yoshitomi Pharmaceutical

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0221211A1 (en) * 1983-08-24 1987-05-13 Unilever Plc Use of secondary amide compounds for the manufacture of medicaments for the treatment of dermatological inflammation
EP0143628A3 (en) * 1983-11-28 1986-10-22 Unilever Plc Process for preparing salicylamide compounds
EP0144204A3 (en) * 1983-12-05 1986-10-22 Unilever Plc Process for preparing salicylamide compounds
GB2174906A (en) * 1985-05-07 1986-11-19 Oreal Topical compositions containing salicylic acid derivatives
US4767750A (en) * 1985-05-07 1988-08-30 L'oreal Topical compositions intended for skin treatment containing salicylic acid derivatives
GB2174906B (en) * 1985-05-07 1989-03-01 Oreal Topical compositions intended for skin treatment based on salicylic acid derivatives
EP0223515A3 (en) * 1985-11-08 1987-12-16 Unilever Plc Oral compositions comprising salicylamides and zinc salts for the synergistic inhibition of dental plaque
EP1328507A4 (en) * 2000-10-02 2005-07-27 Univ New York State Res Found NAPHTHYLSALICYLANILIDES AS ANTIMICROBIAL AND ANTI-INFLAMMATORY AGENTS

Also Published As

Publication number Publication date
EP0038192B2 (en) 1989-12-27
EP0038192B1 (en) 1984-08-15
US4358443A (en) 1982-11-09
DE3165507D1 (en) 1984-09-20

Similar Documents

Publication Publication Date Title
US4358443A (en) Method and composition for controlling the growth of microorganisms
EP0038191B1 (en) 5-acylsalicylanilides derivatives and method for inhibiting the growth of microorganisms
FI873154A0 (en) AMIDDERIVAT.
NZ314508A (en) 1,2-diphenylpyrrole derivatives, preparation and pharmaceutical compositions
FR2391210A1 (en) QUINOLEINECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS
ATE448194T1 (en) USE OF A PHARMACEUTICAL COMPOSITION CONTAINING A PARA-AMINOPHENYLACETIC ACID DERIVATIVE FOR THE TREATMENT OF INFLAMMATORY DISEASES OF THE GASTROINTESTINAL TRACT
FI894566A0 (en) BENZAZEPINER SUBSTITUERADE, DERAS FRAMSTAELLNING OCH DESSA INNEHAOLLANDE PHARMACEUTISKA BLANDNINGAR.
KR890005031A (en) L-dopa derivative or acid addition salt thereof, preparation method thereof and use thereof
KR840007596A (en) Process for preparing salts of organophosphorus derivatives
DE69326395D1 (en) Spirooxathiolan quinuclidine derivative for the treatment of Sjogren's syndrome
EP0198366B1 (en) Novel 5-alkylsulfonylsalicylanlides and microbiocidal compositions for controlling the growth of microorganisms
ATE22078T1 (en) 1-ETHYL-6,8-DIFLUORO-1,4-DIHYDRO-7-(1-IMIDAZOLYL - 4-OXOCHINOLINECARBONIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION AND ANTIBACTERIAL COMPOSITIONS.
US3928509A (en) Hybrid ionic phosphorus compounds
ES482075A1 (en) Bicyclo(3.1.0)hexyl-substituted carbonylaminophenoxy compounds, their preparation, and compositions containing them for use in treating mammals.
SE8304410L (en) CYCLOHEXYLCARBOXYLIC ACID DERIVATIVES AND SETS FOR THEIR PREPARATION
US3184475A (en) Maleimides, maleamides and fumaramides
WO2000027378A3 (en) Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases
US3224936A (en) Pesticidal maleimides, maleamides and fumaramides
US3649718A (en) Halogenated phenyl alkylene phosphinates
JPH0558971A (en) Aminoester compound salt and disinfectant
US3236884A (en) N-methyl glycine derivative of trichlorophenol
GB1374348A (en) Haloalkanesulphonic acid esters and their use in compositions for killing noxious organisms
GB2250989B (en) Thioacid amide derivatives and fodder compositions containing the same
JPH05331058A (en) Fungicide
SU1601985A1 (en) BIS-(β--HYDROXYETHYL)-β--HYDROXY-β--(n-TOLYLOXYMETHYL) ETHYLAMINE MONO (n-TOLYL) AMIDE FUMARIC ACID SALT INHIBITING AGGREGATION OF THROMBOLYTES

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT NL SE

17P Request for examination filed

Effective date: 19811016

ITF It: translation for a ep patent filed
GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Designated state(s): AT BE CH DE FR GB IT LI NL SE

REF Corresponds to:

Ref document number: 8989

Country of ref document: AT

Date of ref document: 19840915

Kind code of ref document: T

REF Corresponds to:

Ref document number: 3165507

Country of ref document: DE

Date of ref document: 19840920

ET Fr: translation filed
PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

26 Opposition filed

Opponent name: BLENDAX-WERKE R. SCHNEIDER GMBH & CO.

Effective date: 19850430

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW

NLR1 Nl: opposition has been filed with the epo

Opponent name: BLENDAX-WERKE R. SCHNEIDER GMBH & CO.

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Effective date: 19851101

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee
ITF It: translation for a ep patent filed
PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 19891227

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE CH DE FR GB IT NL SE

ET3 Fr: translation filed ** decision concerning opposition
ITTA It: last paid annual fee
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 19900919

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19900927

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19901002

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 19901003

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 19901011

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 19901018

Year of fee payment: 10

BERE Be: lapsed

Owner name: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NE

Effective date: 19900430

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19901206

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Effective date: 19910410

Ref country code: GB

Effective date: 19910410

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Effective date: 19910411

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Effective date: 19910430

Ref country code: CH

Effective date: 19910430

Ref country code: LI

Effective date: 19910430

BERE Be: lapsed

Owner name: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NE

Effective date: 19910430

GBPC Gb: european patent ceased through non-payment of renewal fee
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Effective date: 19911230

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Effective date: 19920201

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

EUG Se: european patent has lapsed

Ref document number: 81301586.4

Effective date: 19911108